Publications

  1. Dolman ME, van Dorenmalen KM, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Bovenschen N, Storm G, Hennink WE, Kok RJ
    Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue.
    MACROMOLECULAR BIOSCIENCE 12: pp. 93-103. (2012)
    IF: 3.458 (2010)
  2. Nemeth G, Varga Z, Greff Z, Bencze G, Sipos A, Szantai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmary Z, Minarovits J, Keri G, Orfi L
    Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection.
    CURRENT MEDICINAL CHEMISTRY 18: pp. 342-358. (2011)
    IF: 4.708 (2010)
  3. Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Keri G, Schaeffter T, Goh V, O Doherty MJ, Ellisb PA, Ng T
    The challenges of integrating molecular imaging into the optimization of cancer therapy.
    INTEGRATIVE BIOLOGY 3: pp. 603-631. (2011)
    IF: 4.439 (2010)
  4. Harmsen S, Dolman MEM, Nemes Z, Lacombe M, Szokol B, Pato J, Keri G, Orfi L, Storm G, Hennink WE, Kok RJ
    Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate.
    BIOCONJUGATE CHEMISTRY 22: pp. 540-545. (2011)
    IF: 5.002 (2010)
  5. Gajda Z, Torok R, Horvath Z, Szantai-Kis C, Orfi L, Keri G, Szente M
    Protein kinase inhibitor as a potential candidate for epilepsy treatment.
    EPILEPSIA 52: pp. 579-588. (2011)
    IF: 3.955 (2010)
  6. Fruhwirth GO, Fernandes LP, Weitsman G, Patel G, Kelleher M, Lawler K, Brock A, Poland SP, Matthews DR, Keri G, Barber PR, Vojnovic B, Ameer-Beg SM, Coolen ACC, Fraternali F, Ng T
    How Forster Resonance Energy Transfer Imaging Improves the Understanding of Protein Interaction Networks in Cancer Biology.
    CHEMPHYSCHEM 12: pp. 442-462. (2011)
    IF: 3.339 (2010)
  7. Chatterjee J, Laufer B, Beck JG, Helyes Z, Pinter E, Szolcsanyi J, Horvath A, Mandl J, Reubi JC, Keri G, Kessler H
    N-Methylated sst(2) Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.
    ACS MEDICINAL CHEMISTRY LETTERS 2: pp. 509-514. (2011)
  8. Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub, H
    Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
    JOURNAL OF PROTEOME RESEARCH 9:(11) pp. 6033-6043. (2010)
    IF: 5.460
  9. Magnet S, Hartkoorn RC, Szekely R, Pato J, Triccas JA, Schneider P, Szantai-Kis C, Orfi L, Chambon M, Banfi D, Bueno M, Turcatti G, Keri G, Cole, ST
    Leads for antitubercular compounds from kinase inhibitor library screens.
    TUBERCULOSIS 90:(6) pp. 354-360. (2010)
    IF: 2.650
  10. d'Angelo I, Garcia-Fuentes M, Parajo Y, Welle A, Vantus T, Horvath A, Bokonyi G, Keri G, Alonso MJ
    Nanoparticles Based on PLGA:Poloxamer Blends for the Delivery of Proangiogenic Growth Factors.
    MOLECULAR PHARMACEUTICS 7:(5) pp. 1724-1733. (2010)
    IF: 5.400
  11. Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, Keri G
    Small-Molecule Inhibitors of NADPH Oxidase 4.
    JOURNAL OF MEDICINAL CHEMISTRY 53:(18) pp. 6758-6762. (2010)
    IF: 5.207
  12. Varga Z, Berenyi S, Szokol B, Orfi L, Keri G, Petak I, Hoell A, Bota A
    A Closer Look at the Structure of Sterically Stabilized Liposomes: A Small-Angle X-ray Scattering Study.
    JOURNAL OF PHYSICAL CHEMISTRY B - CONDENSED MATTER MATERIALS SURFACES AND BIOPHYSICAL 114:(20) pp. 6850-6854. (2010)
    IF: 3.603
  13. Sharma K, Kumar C, Keri G, Breitkopf SB, Oppermann FS, Daub H
    Quantitative Analysis of Kinase-Proximal Signaling in Lipopolysaccharide-Induced Innate Immune Response.
    JOURNAL OF PROTEOME RESEARCH 9:(5) pp. 2539-2549. (2010)
    IF: 5.460
  14. Schreiber TB, Mausbacher N, Keri G, Cox J, Daub H
    An Integrated Phosphoproteomics Work Flow Reveals Extensive Network Regulation in Early Lysophosphatidic Acid Signaling.
    MOLECULAR & CELLULAR PROTEOMICS 9:(6) pp. 1047-1062. (2010)
    IF: 8.354
  15. Petak I, Schwab R, Orfi L, Kopper L, Keri G
    Integrating molecular diagnostics into anticancer drug discovery.
    NATURE REVIEWS DRUG DISCOVERY 9:(7) pp. 523-535. (2010)
    IF: 28.712
  16. Huszar M, Varga A, Horvath A, Lorand T, Agocs A, Idei M, Mandl J, Vantus T, Keri G
    Comparative characterization of experimental and calculated lipophilicity and anti-tumour activity of isochromanone derivatives.
    CURRENT MEDICINAL CHEMISTRY 17:(4) pp. 321-333. (2010)
    IF: 4.630
  17. d Angelo I, Parajo Y, Horvath A, Keri G, La Rotonda MI, Alonso MJ
    Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles.
    JOURNAL OF MICROENCAPSULATION 27:(1) pp. 57-66. (2010)
    IF: 1.515
  18. Zsila F, Fitos I, Bencze G, Keri G, Orfi L
    Determination of Human Serum alpha(1)-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors.
    CURRENT MEDICINAL CHEMISTRY 16:(16) pp. 1964-1977. (2009)
    IF: 4.708
  19. Orban-Kis K, Antal K, Simon A, Keri G, Szilagyi T, Kardos J, Emri Z
    MODULATION OF HIPOCAMPAL SYNAPTIC CURRENTS AND INTRACELLULAR Ca2+ LEVELS BY SOMATOSTATIN ANALOGUES.
    THE JOURNAL OF PHYSIOLOGICAL SCIENCES 59: p. 153. (2009)
    IF: 1.125
  20. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H
    Large-scale proteomics analysis of the human kinome.
    MOLECULAR & CELLULAR PROTEOMICS 8:(7) pp. 1751-1764. (2009)
    IF: 8.791
  21. Kirti Sharma, Christoph Weber, Michaela Bairlein, Zoltán Greff, György Kéri, Jürgen Cox, Jesper V Olsen, Henrik Daub
    Proteomics strategy for quantitative protein interaction profiling in cell extracts.
    NATURE METHODS 6:(10) pp. 741-744. (2009)
    IF: 16.874
  22. Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Keri G, Ellis PA, Ng T
    The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
    TARGETED ONCOLOGY 4: pp. 235-252. (2009)
    IF: 0.455
  23. Herczenik E, Varga Z, Eros D, Mako V, Oroszlan M, Rugonfalvi-Kiss S, Romics L, Fust G, Keri G, Orfi L, Cervenak L
    Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors.
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH 29:(2) pp. 75-83. (2009)
    IF: 1.517
  24. Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, Banhegyi P, Szabo GV, Varkondi E, Petak I, Orfi L, Keri G
    Tyrosine kinase inhibitors - Small molecular weight compounds inhibiting EGFR.
    CURRENT OPINION IN MOLECULAR THERAPEUTICS 10:(3) pp. 308-321. (2009)
    IF: 3.452
  25. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B
    Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    BRITISH JOURNAL OF PHARMACOLOGY 158:(4) pp. 1153-1164. (2009)
    IF: 5.204
  26. Eros D, Orfi L, Csuka I, Keri G, Hrabak A
    Binding specificity of the l-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1.
    AMINO ACIDS 36:(3) pp. 483-492. (2009)
    IF: 3.877
  27. Donkó A, Orient A, Szabó PT, Németh G, Vántus T, Kéri G, Orfi L, Hunyady L, Buday L, Geiszt M
    Detection of hydrogen peroxide by lactoperoxidase-mediated dityrosine formation.
    FREE RADICAL RESEARCH 43:(5) pp. 440-445. (2009)
    IF: 2.215
  28. d’Angelo I, Parajo Y, Horvath A, Keri G, La Rotonda MI, Alonso MJ
    Improved delivery of antiangiogenic drug from PLGA: poloxamer blend micro and nanoparticles.
    JOURNAL OF MICROENCAPSULATION (2009)
    IF: 1.890
  29. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Keri G, Ullrich A
    AXL is a potential target for therapeutic intervention in breast cancer progression.
    CANCER RESEARCH 68:(6) pp. 1905-1915. (2008)
    IF: 7.514
  30. Varkondi E, Pinter F, Robert K, Schwab R, Breza N, Orfi L, Keri G, Petak I
    Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH 28:(3) pp. 295-306. (2008)
    IF: 1.540
  31. Tejeda M, Gaal D, Hullan L, Csuka O, Schwab R, Szokoloczi O, Keri G
    Continuous Administration of the Somatostatin Structural Derivative vertical bar TT-232 vertical bar by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human Tumor Models.
    ANTICANCER RESEARCH 28:(5A) pp. 2769-2774. (2008)
    IF: 1.390
  32. Szekely R, Waczek F, Szabadkai I, Nemeth G, Hegymegi-Barakonyi B, Eros D, Szokol B, Pato J, Hafenbradl D, Satchell J, Saint-Joanis B, Cole ST, Orfi L, Klebl BM, Keri G
    A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling.
    IMMUNOLOGY LETTERS 116:(2) pp. 225-231. (2008)
    IF: 2.858
  33. Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I
    Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
    JOURNAL OF MOLECULAR DIAGNOSTICS 10:(2) pp. 160-168. (2008)
    IF: 3.643
  34. Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vantus T, Bokonyi G, Szabo E, Horvath A, Keri G, Okada Y
    Synthesis of somatostatin analogues containing C-terminal adamantane and their antiproliferative properties.
    JOURNAL OF MEDICINAL CHEMISTRY 51:(16) pp. 5121-5124. (2008)
    IF: 4.898
  35. Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vantus T, Bokonyi G, Szabo E, Horvath A, Keri G, Okada Y
    New cyclic somatostatin analogues containing a pyrazinone ring: Importance of Tyr for antiproliferative activity.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 18:(23) pp. 6199-6201. (2008)
    IF: 2.531
  36. Hegymegi-Barakonyi B, Szekely R, Varga Z, Kiss R, Borbely G, Nemeth G, Banhegyi P, Pato J, Greff Z, Horvath Z, Meszaros G, Marosfalvi J, Eros D, Szantai-Kis C, Breza N, Garavaglia S, Perozzi S, Rizzi M, Hafenbradl D, Ko M, Av-Gay Y, Klebl BM, Orfi L, Keri G
    Signalling Inhibitors Against Mycobacterium tuberculosis - Early Days of a New Therapeutic Concept in Tuberculosis.
    CURRENT MEDICINAL CHEMISTRY 15:(26) pp. 2760-2770. (2008)
    IF: 4.823
  37. Futosi K, Orfi L, Keri G, Mocsai A, Vantus T
    Development and characterization of potential anti-inflammatory compounds using in vitro functional screening of neutrophils.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 38: pp. 74-75. (2008)
    IF: 2.784
  38. Eros D, Szantai-Kis C, Kiss R, Keri G, Hegymegi-Barakonyi B, Kovesdi I, Orfi L
    Structure-activity relationships of PDE5 inhibitors.
    CURRENT MEDICINAL CHEMISTRY 15:(16) pp. 1570-1585. (2008)
    IF: 4.823
  39. Elekes K, Helyes Z, Kereskai L, Sandor K, Pinter E, Pozsgai G, Tekus V, Banvolgyi A, Nemeth J, Szuts T, Keri G, Szolcsany J
    Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse.
    EUROPEAN JOURNAL OF PHARMACOLOGY 578:(2-3) pp. 313-322. (2008)
    IF: 2.787
  40. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M
    Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
    MOLECULAR CELL 31:(3) pp. 438-448. (2008)
    IF: 12.903
  41. Breza N, Pato J, Orfi L, Hegymegi-Barakonyi B, Banhegyi P, Varkondi E, Borbely G, Petak I, Keri G
    Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases.
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH 28:(4) pp. 361-373. (2008)
    IF: 1.540
  42. Banhegyi P, Waczek F, Szekelyhidi Z, Hegymegi-Barakonyi B, Keri G, Orfi L
    New method for the synthesis of 2-acylamino-1-benzothiophene-3-carboxamide derivatives from the corresponding esters.
    SYNTHETIC COMMUNICATIONS 38:(19) pp. 3270-3276. (2008)
    IF: 0.981
  43. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J
    Signaling through RAS-RAF-MEK-ERK: from basics to bedside.
    CURRENT MEDICINAL CHEMISTRY 14:(5) pp. 601-623. (2007)
    IF: 4.944
  44. Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, Keri G, Wehland J, Daub H
    Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.
    MOLECULAR & CELLULAR PROTEOMICS 6:(3) pp. 537-547. (2007)
    IF: 9.425
  45. Tejeda M, Gaal D, Hullan L, Schwab R, Szokoloczi O, Keri G
    Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
    ANTICANCER RESEARCH 27:(6B) pp. 4015-4019. (2007)
    IF: 1.414
  46. Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A
    Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death.
    CANCER RESEARCH 67:(4) pp. 1602-1608. (2007)
    IF: 7.672
  47. Simon A, Keri G, Kardos J
    Comparison of the binding modes of TT-232 in somatostatin receptors type 1 and 4.
    JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM 816:(1-3) pp. 73-76. (2007)
    IF: 1.112
  48. Schwab R, Micsik T, Szokoloczi O, Schafer E, Tihanyi B, Tihanyi T, Kupcsulik P, Diofalvi K, Mersich T, Besznyak I, Zarand A, Mihalik R, Sarkadi B, Keri G, Pap A, Jakab F, Kopper L, Petak I
    Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 5:(4) pp. 541-550. (2007)
    IF: 1.832
  49. Hallgas B, Dobos Z, Agocs A, Idei M, Keri G, Lorand T, Meszaros G
    Lipophilicity and antiproliferative activity profiling of 2-benzylidencycloalkanones.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 856:(1-2) pp. 148-155. (2007)
    IF: 2.647
  50. Gonzalo T, Beljaars L, van de Bovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DKF, Lacombe M, Opdam F, Keri G, Orfi L, Poelstra K, Kok RJ
    Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 321:(3) pp. 856-865. (2007)
    IF: 4.003
  51. Temming K, Lacombe M, Schaapveld RQJ, Orfi L, Keri G, Poelstra K, Molema G, Kok RJ
    Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.
    CHEMMEDCHEM 1:(11) pp. 1200-1203. (2006)
  52. Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers ECF, Orfi L, Keri G, Poelstra K, Molema G, Kok RJ
    Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug - Albumin conjugates using platinum(II)-based drug linker technology.
    BIOCONJUGATE CHEMISTRY 17:(5) pp. 1246-1255. (2006)
    IF: 3.823
  53. Tejeda M, Gaal D, Hullan L, Hegymegi-Barakonyi B, Keri G
    Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
    ANTICANCER RESEARCH 26:(5A) pp. 3477-3483. (2006)
    IF: 1.479
  54. Tejeda M, Gaal D, Hullan L, Csuka O, Schwab R, Szokoloczi O, Keri G
    A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
    ANTICANCER RESEARCH 26:(4B) pp. 3011-3015. (2006)
    IF: 1.479
  55. Szantai Kis C, Kovesdi I, Eros D, Banhegyi P, Ullrich A, Keri G, Orfi L
    Prediction oriented QSAR modelling of EGFR inhibition.
    CURRENT MEDICINAL CHEMISTRY 13:(3) pp. 277-287. (2006)
    IF: 5.207
  56. Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld RQJ, de Borst MH, van Goor H, Henning RH, Proost JH, Moolenaar F, Keri G, Meijer DKF, Poelstra K, Kok RJ
    Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole in renal tubular cells: A novel strategy to treat renal fibrosis.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 319:(1) pp. 8-19. (2006)
    IF: 3.956
  57. Kéri Gy, Orfi L, Eros D, Hegymegi-Barakonyi B, Szántai-Kis Cs, Horváth Z, Wáczek F, Marosfalvy J, Szabadkai I, Pató J, Greff Z, Hafenbradl D, Daub H, Müller G, Klebl B, Ullrich A
    Signal Transduction Therapy with Rationally Designed Kinase Inhibitors.
    CURRENT SIGNAL TRANSDUCTION THERAPY 1:(1) pp. 67-95. (2006)
  58. Hrabak A, Bokonyi G, Orfi L, Bajor T, Keri G
    Comparison of the cytotoxic effects of receptor tyrosine kinase inhibitors on macrophage functions; possible side effects in the immune defense.
    IMMUNOLOGY LETTERS 107:(2) pp. 169-175. (2006)
    IF: 2.352
  59. Hollosy F, Valko K, Hersey A, Nunhuck S, Keri G, Bevan C
    Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning.
    JOURNAL OF MEDICINAL CHEMISTRY 49:(24) pp. 6958-6971. (2006)
    IF: 5.115
  60. Varkondi E, Schafer E, Bokonyi G, Gyokeres T, Orfi L, Petak I, Pap A, Szokoloczi O, Keri G, Schwab R
    Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors.
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH 25:(1) pp. 45-56. (2005)
    IF: 2.000
  61. Tejeda M, Gaal D, Csuka O, Keri G
    Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
    ANTICANCER RESEARCH 25:(1A) pp. 325-330. (2005)
    IF: 1.604
  62. Szokoloczi O, Schwab R, Petak I, Orfi L, Pap A, Eberle A N, Szuts T, Keri G
    TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases.
    JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH 25:(4-6) pp. 217-235. (2005)
    IF: 2.000
  63. Szekelyhidi Z, Pato J, Waczek F, Banhegyi P, Hegymegi Barakonyi B, Eros D, Meszaros G, Hollosy F, Hafenbradl D, Obert S, Klebl B, Keri G, Orfi L
    Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 15:(13) pp. 3241-3246. (2005)
    IF: 2.478
  64. Szakacs Z, Beni S, Varga Z, Orfi L, Keri G, Noszal B
    Acid-base profiling of imatinib (Gleevec) and its fragments.
    JOURNAL OF MEDICINAL CHEMISTRY 48:(1) pp. 249-255. (2005)
    IF: 4.926
  65. Sukopp M, Schwab R, Marinelli L, Biron E, Heller M, Varkondi E, Pap A, Novellino E, Keri G, Kessler H
    Structure-activity relationship studies optimizing the antiproliferative activity of novel cyclic somatostatin analogues containing a restrained cyclic beta-amino acid.
    JOURNAL OF MEDICINAL CHEMISTRY 48:(8) pp. 2916-2926. (2005)
    IF: 4.926
  66. Simon Á, Czajlik A, Perczel A, Kéri Gy, Nyikos L, Emri Zs, Kardos J
    Description of the somatostatin analogue TT-232 binding crevice in a homology model of type 1 somatostatin receptor.
    IDEGGYÓGYÁSZATI SZEMLE/CLINICAL NEUROSCIENCE 58:(S1) pp. 1-112. (2005)
  67. Schwab R, Pinter F, Moldavy J, Papay J, Strausz J, Kopper L, Keri G, Pap A, Petak I, Oreskovich K, Mangel L
    Case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
    JOURNAL OF CLINICAL ONCOLOGY 23:(30) pp. 7736-7738. (2005)
    IF: 11.810
  68. Keri G, Schwab R, Szokoloczi O, Szuts T, Szolcsanyi J
    TT-232: An anti-tumour and anti-inflammatory peptide therapeutic in clinical development.
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS 11:(1) pp. 3-15. (2005)
  69. Keri G, Szekelyhidi Z, Banhegyi P, Varga Z, Hegymegi Barakonyi B, Szantai Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Eros D, Horvath Z, Greff Z, Marosfalvi J, Pato J, Szabadkai I, Szilagyi I, Szegedi Z, Varga I, Waczek F, Orfi L
    Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3:(5) pp. 543-551. (2005)
    IF: 2.060
  70. Hallgas B, Dobos Z, Osz E, Hollosy F, Schwab R E, Szabo E Z, Eros D, Idei M, Keri G, Lorand T
    Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 819:(2) pp. 283-291. (2005)
    IF: 2.391
  71. Godl K, Gruss O J, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horvath Z, Keri G, Muller S, Cotten M, Ullrich A, Daub H
    Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.
    CANCER RESEARCH 65:(15) pp. 6919-6926. (2005)
    IF: 7.616
  72. Elkind N B, Szentpetery Z, Apati A, Ozvegy Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B
    Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    CANCER RESEARCH 65:(5) pp. 1770-1777. (2005)
    IF: 7.616
  73. Dobos Z, Kiss E, Hallgas B, Keri G, Idei M
    Micellar proportion: A parameter to compare the hydrophobicity of the pseudostationary phases or that of the analytes in micellar electrokinetic chromatography.
    ELECTROPHORESIS 26:(4-5) pp. 849-857. (2005)
    IF: 3.850
  74. Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A
    Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival.
    EMBO REPORTS 6:(1) pp. 63-69. (2005)
    IF: 7.663
  75. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H
    Cellular targets of gefitinib.
    CANCER RESEARCH 65:(2) pp. 379-382. (2005)
    IF: 7.616
  76. Varkondi E, Juhasz H, Nagy K, Schwab R, Pap A, Kopper L, Keri G, Petak I
    Preparation of human EGFR intracellular domain-GST fusion protein with recombinant technique.
    TISSUE ANTIGENS 64: pp. 431-432. (2004)
  77. Vantus T, Vertommen D, Saelens X, Rykx A, de Kimpe L, Vancauwenbergh S, Mikhalap S, Waelkens E, Keri G, Seufferlein T, Vandenabeele P, Rider M H, Vandenheede J R, van Lint J
    Doxorubicin-induced activation of protein kinase D1 through caspase-mediated proteolytic cleavage: identification of two cleavage sites by microsequencing.
    CELLULAR SIGNALLING 16:(6) pp. 703-709. (2004)
    IF: 4.741
  78. Szolcsanyi J, Bolcskei K, Szabo A, Pinter E, Petho G, Elekes K, Borzsei R, Almasi R, Szuts T, Keri G, Helyes Z
    Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia.
    EUROPEAN JOURNAL OF PHARMACOLOGY 498:(1-3) pp. 103-109. (2004)
    IF: 2.432
  79. Simon A, Czajlik A, Perczel A, Keri G, Nyikos L, Emri Z, Kardos J
    Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 316: pp. 1059-1064. (2004)
    IF: 2.904
  80. Schwab R, Pinter F, Aladics B, Oreskovich K, Moldvay J, Kopper L, Pap A, Keri G, Petak I
    Full clinical response of brain metastases in bronchoalveolar cancer to EGFR inhibitory treatment.
    TISSUE ANTIGENS 64: p. 389. (2004)
    IF: 1.990
  81. Ozvegy Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz J D, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B
    High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
    MOLECULAR PHARMACOLOGY 65:(6) pp. 1485-1495. (2004)
    IF: 5.080
  82. Orfi L, Waczek F, Pato J, Varga I, Hegymegi Barakonyi B, Houghten R A, Keri G
    Improved, high yield synthesis of 3H-quinazolin-4-ones, the key intermediates of recently developed drugs.
    CURRENT MEDICINAL CHEMISTRY 11:(19) pp. 2549-2553. (2004)
    IF: 4.382
  83. Miyazaki A, Yokoi T, Tachibana Y, Enomoto R, Lee E, Bokonyi G, Keri G, Tsuda Y, Okada Y
    Design and synthesis of novel type somatostatin analogs with antiproliferative activities on A431 tumor cells.
    TETRAHEDRON LETTERS 45:(33) pp. 6323-6327. (2004)
    IF: 2.484
  84. Hollosy F, Keri G
    Plant-derived protein tyrosine kinase inhibitors as anticancer agents.
    CURRENT MEDICINAL CHEMISTRY - ANTI-CANCER AGENTS 4:(2) pp. 173-197. (2004)
  85. Helyes Z, Szabo A, Nemeth J, Jakab B, Pinter E, Banvolgyi A, Kereskai L, Keri G, Szolcsanyi J
    Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat.
    ARTHRITIS AND RHEUMATISM 50:(5) pp. 1677-1685. (2004)
    IF: 7.414
  86. Hallgas B, Patonay T, Kiss Szikszai A, Dobos Z, Hollosy F, Eros D, Orfi L, Keri G, Idei M
    Comparison of measured and calculated lipophilicity of substituted aurones and related compounds.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 801:(2) pp. 229-235. (2004)
    IF: 2.176
  87. Eros D, Orfi L, Keri G
    Rational drug design and signal transduction therapy.
    PHARMACHEM 3:(1) pp. 27-30. (2004)
  88. Eros D, Keri G, Kovesdi I, Szantai Kis C, Meszaros G, Orfi L
    Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods.
    MINI-REVIEWS IN MEDICAL CHEMISTRY 4:(2) pp. 167-177. (2004)
  89. Dobos Z, Lorand T, Hollosy F, Hallgas B, Eros D, Meszaros G, Keri G, Idei M
    Determination of the basicity of Mannich ketones by capillary electrophoresis.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 799:(1) pp. 179-183. (2004)
    IF: 2.176
  90. Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, Keri G, Ullrich A, Daub H
    Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
    CHEMISTRY & BIOLOGY 11:(5) pp. 691-701. (2004)
    IF: 5.725
  91. Tejeda M, Gaal D, Csuka O, Ullrich A, Schwab R, Pap A, Horvath A, Keri G
    The antitumor effect of the somatostatin analogue TT-232 depends on the treatment regimen.
    CANCER DETECTION AND PREVENTION 27:(2) pp. 155-162. (2003)
    IF: 1.180
  92. Tejeda M, Gaal D, Barna K, Csuka O, Keri G
    The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
    ANTICANCER RESEARCH 23:(5A) pp. 4061-4066. (2003)
    IF: 1.347
  93. Szende B, Keri G
    TT-232: a somatostatin structural derivative as a potent antitumor drug candidate.
    ANTI-CANCER DRUGS 14:(8) pp. 585-588. (2003)
    IF: 1.938
  94. Szende B, Horvath A, Bokonyi G, Keri G
    Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
    BRITISH JOURNAL OF CANCER 88:(1) pp. 132-136. (2003)
    IF: 3.894
  95. Szantai Kis C, Kovesdi I, Keri G, Orfi L
    Validation subset selections for extrapolation oriented QSPAR models.
    MOLECULAR DIVERSITY 7:(1) pp. 37-43. (2003)
  96. Keri G, Racz G, Magyar K, Orfi L, Horvath A, Schwab R, Hegymegi B B, Szende B
    Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction.
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 1010: pp. 109-112. (2003)
    IF: 1.892
  97. Idei M, Kiss E, Dobos Z, Hallgas B, Meszaros G, Hollosy F, Keri G
    Separation of anti-tumor peptides by capillary electrophoresis in organic solvent containing background electrolytes.
    ELECTROPHORESIS 24:(5) pp. 829-833. (2003)
    IF: 4.040
  98. Szende B, Okada Y, Tsuda Y, Horvath A, Bokonyi G, Okamoto S, Wanaka K, Keri G
    A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number.
    IN VIVO 16:(5) pp. 281-286. (2002)
    IF: 1.115
  99. Pinter E, Helyes Z, Nemeth J, Porszasz R, Petho G, Than M, Keri G, Horvath A, Jakab B, Szolcsanyi J
    Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 366:(2) pp. 142-150. (2002)
    IF: 2.566
  100. Hollosy F, Lorand T, Orfi L, Eros D, Keri G, Idei M
    Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high-performance liquid chromatography, clogP calculation and cytotoxicity test.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 768:(2) pp. 361-368. (2002)
    IF: 1.913
  101. Hollosy F, Seprodi J, Orfi L, Eros D, Keri G, Idei M
    Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries.
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 780:(2) pp. 355-363. (2002)
    IF: 1.913
  102. Hollosy F, Lorand T, Orfi L, Eros D, Keri G, Idei M
    Evaluation of hydrophobicity and antitumor activity of a molecule library of Mannich ketones of cycloalkanones.
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 25:(7) pp. 1129-1143. (2002)
    IF: 0.810
  103. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G
    Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1587:(2-3) pp. 318-325. (2002)
    IF: 3.300
  104. Eros D, Kovesdi I, Orfi L, Takacs Novak K, Acsady G, Keri G
    Reliability of logP predictions based on calculated molecular descriptors: A critical review.
    CURRENT MEDICINAL CHEMISTRY 9:(20) pp. 1819-1829. (2002)
    IF: 4.966
  105. Vantus T, Keri G, Krivickiene Z, Valius M, Stetak A, Keppens S, Csermely P, Bauer PI, Bokonyi G, Declercq W, Vandenabeele P, Merlevede W, Vandenheede Jr
    The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases.
    CELLULAR SIGNALLING 13: pp. 717-725. (2001)
    IF: 3.398
  106. Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K
    Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites.
    JOURNAL OF NEURAL TRANSMISSION 108:(1) pp. 25-33. (2001)
    IF: 1.862
  107. Stetak A, Lankenau A, Vantus T, Csermely P, Ullrich A, Keri G
    The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 285: pp. 483-488. (2001)
    IF: 2.946
  108. Stetak A, Csermely P, Ullrich A, Kéri G
    Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 288: pp. 564-572. (2001)
    IF: 2.946
  109. Schwab RE, Froidevaux S, Paku S, Tejeda M, Szende B, Pap A, Beglinger C, Eberle AN, Keri G
    Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
    ANTICANCER RESEARCH 21:(1A) pp. 71-75. (2001)
    IF: 1.416
  110. Koncz G, Toth G K, Bokonyi G, Keri G, Pecht I, Medgyesi D, Gergely J, Sarmay G
    Co-clustering of Fc gamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein.
    EUROPEAN JOURNAL OF BIOCHEMISTRY 268:(14) pp. 3898-3906. (2001)
    IF: 2.849
  111. Idei M, Kiss E, Hollosy F, Tamas B, Orfi L, Seprodi J, Meszaros G, Keri G
    Calculation of phase residence times in micellar electrokinetic chromatography.
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 24:(3) pp. 303-315. (2001)
    IF: 0.762
  112. Hollosy F, Idei M, Csorba G, Szabo E, Bokonyi G, Seprodi A, Meszaros G, Szende B, Keri G
    Activation of caspase-3 protease during the process of ursolic acid and its derivative-induced apoptosis.
    ANTICANCER RESEARCH 21:(5) pp. 3485-3491. (2001)
    IF: 1.416
  113. Helyes Z, Pinter E, Nemeth J, Keri G, Than M, Oroszi G, Horvath A, Szolcsanyi J
    Anti-inflammatory effect of synthetic somatostatin analogues in the rat.
    BRITISH JOURNAL OF PHARMACOLOGY 134:(7) pp. 1571-1579. (2001)
    IF: 3.502
  114. Gruner S A W, Keri G, Schwab R, Venetianer A, Kessler H
    Sugar amino acid containing somatostatin analogues that induce apoptosis in both drug-sensitive and multidrug-resistant tumor cells.
    ORGANIC LETTERS 3:(23) pp. 3723-3725. (2001)
    IF: 3.670
  115. Tompa A, Jakab M G, Major J, Idei M, Bocsi J, Mihalik R, Szende B, Keri G
    The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes.
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 465:(1-2) pp. 61-68. (2000)
    IF: 1.506
  116. Tejeda M, Gaal D, Schwab R E, Pap A, Szuts T, Keri G
    Influence of various aministration routes on the antitumor efficacy of TT-232, a novel somatostatin analog.
    ANTICANCER RESEARCH 20:(2A) pp. 1023-1027. (2000)
    IF: 1.331
  117. Okada Y, Tsuda Y, Wanaka K, Tada M, Okamoto U, Okamoto S, Hijikata Okunomiya A, Bokonyi G, Szende B, Keri G
    Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (Melanoma) and HT29 cell lines.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 10:(19) pp. 2217-2221. (2000)
    IF: 1.927
  118. Hollosy F, Meszaros G, Bokonyi G, Idei M, Seprodi A, Szende B, Keri G
    Cytostatic, cytotoxic and protein tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells.
    ANTICANCER RESEARCH 20:(6B) pp. 4563-4570. (2000)
    IF: 1.331
  119. Helyes Z, Than M, Oroszi G, Pinter E, Nemeth J, Keri G, Szolcsanyi J
    Anti-nociceptive effect induced by somatostatin released from sensory nerve terminals and by synthetic somatostatin analogues in the rat.
    NEUROSCIENCE LETTERS 278:(3) pp. 185-188. (2000)
    IF: 2.091
  120. Toth I, Malkinson J P, Flinn N S, Drouillat B, Horvath A, Erchegyi J, Idei M, Venetianer A, Artursson P, Lazorova L, Szende B, Keri G
    Novel lipoamino acid- and liposaccharide-based system for peptide delivery: Application for oral administration of tumor-selective somatostatin analogues.
    JOURNAL OF MEDICINAL CHEMISTRY 42:(19) pp. 4010-4013. (1999)
    IF: 4.079
  121. Tejeda M, Gaal D, Schwab R E, Pap A, Keri G Y
    In vivo antitumor activity of TT-232 a novel somatostatin analog.
    ANTICANCER RESEARCH 19:(4B) pp. 3265-3268. (1999)
    IF: 1.375
  122. Szegedi Z, Takacs J, Szende B, Vadasz Z, Horvath A, Gulyas E, Toth G, Petak I, Bocsi J, Keri G
    A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.
    ENDOCRINE 10:(1) pp. 25-34. (1999)
    IF: 1.533
  123. Orfi L, Waczek F, Szabo M, Kovesdi I, Meszaros G, Idei M, Horvath A, Hollosy F, Mak M, Szegedi Z, Szende B, Keri G, Noszal B
    Potencialis daganatellenes hatású vegyületek elôállítása és vizsgálata Preparation and characterization of potential antineoplastic agents.
    ACTA PHARMACEUTICA HUNGARICA 69:(3) pp. 115-122. (1999)
  124. Orfi L, Waczek F, Kovesdi I, Meszaros G, Idei M, Horvath A, Hollosy F, Mak M, Szegedi Z, Szende B, Keri G
    New antitumor leads from a peptidomimetic library.
    LETTERS IN PEPTIDE SCIENCE 6:(5-6) pp. 325-333. (1999)
    IF: 0.700
  125. Kunvari M, Paska C, Laszlo M, Orfi L, Kovesdi I, Eros D, Bokonyi G, Keri G, Gyurjan I
    Biological activity and structure of antitumor compounds from Plantago media L.
    ACTA PHARMACEUTICA HUNGARICA 69:(5) pp. 232-239. (1999)
  126. Idei M, Gyorffy E, Kiss E, Orfi L, Seprodi J, Tamas B, Hollosy F, Meszaros G, Keri G
    A novel normalized retention factor in micellar electrokinetic chromatography.
    ELECTROPHORESIS 20:(7) pp. 1561-1567. (1999)
    IF: 3.447
  127. Diaconu C C, Szathmari M, Keri G, Venetianer A
    Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.
    BRITISH JOURNAL OF CANCER 80:(8) pp. 1197-1203. (1999)
    IF: 3.282